No Data
No Data
Firebrick Pharma Raises AU$800,000 via Placement
Firebrick Pharma (ASX:FRE) received binding commitments for a placement of AU$800,000 from a substantial shareholder, comprising 16 million shares at a discounted price of AU$0.05 apiece, according to
Firebrick Pharma Sees Substantial Holder up Stake to 12% in Placement
Betadine-like nasal spray provider Firebrick Pharma (ASX:FRE) – whose flagship product Nasodine has recently gone live for sale in the US – has raised $0.8M in a placement largely backed by an existing substantial holder.
Firebrick Pharma Appoints Auditor
Firebrick Pharma (ASX:FRE) appointed BDO Audit as company auditor, according to a Monday filing with the Australian bourse. The appointment follows the resignation of BDO Audit (WA) in line with the f
Firebrick Pharma Launches Antiseptic Nasal Spray Into US Online Market
An antiseptic nasal spray developed by Melbourne-based Firebrick Pharma (ASX: FRE) to attack the common cold has been officially launched online for US customers.
Stocks of the Hour: Firebrick Pharma, Critical Resources, Blue Star Helium
Firebrick Pharma (ASX:FRE) has announce that its Nasodine Nasal Spray product is being launched in the United States today. The product will be promoted for "nasal hygiene" without any therapeutic cla
Firebrick Pharma's Nasodine Nasal Spray Enters US Market
Firebrick Pharma (ASX:FRE) is launching its Nasodine nasal spray in the US Wednesday, according to a same-day Australian bourse filing. The nasal spray can now be purchased from the company's US websi
No Data